New stock news | Weijian Health Pharmacy submits a secondary listing application to the Hong Kong Stock Exchange

According to the disclosure by the Hong Kong Stock Exchange on June 25, Vellness International Holdings Group Limited (referred to as "Vellness Pharmaceuticals") has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Huatai International as its exclusive sponsor. This is the company's second time submitting the application, having previously submitted an application on November 7, 2025. The prospectus shows that Vellness Pharmaceuticals is a comprehensive pharmaceutical company in China specializing in the treatment of kidney diseases, with increasingly strong capabilities in drug development, production, and commercialization. The company is dedicated to providing diversified treatment options for kidney and blood diseases, as well as other major diseases. The company has built a diverse and differentiated product portfolio, covering a wide range of kidney disease areas and extending to other major disease areas such as blood, respiratory, and skin diseases.